Literature DB >> 23983923

Melperone in treatment-refractory schizophrenia: a case series.

Eromona Whiskey1, Marta Vavrova, Fiona Gaughran, David Taylor.   

Abstract

OBJECTIVE: Clozapine is the treatment of choice in refractory schizophrenia, but a substantial proportion of patients experience inadequate response or tolerate the drug poorly. Melperone has been suggested as a possible alternative in such patients. This case series examines the efficacy of melperone in refractory schizophrenia.
METHOD: All patients prescribed melperone at the South London and Maudsley NHS Foundation Trust were identified using a pharmacy database. The main outcome was to determine the proportion of patients discharged on melperone.
RESULTS: Three of 21 patients were discharged on melperone. The primary reason for discontinuation was lack of efficacy.
CONCLUSION: Melperone may be an option in a very few patients with refractory schizophrenia, but it should not be considered as an alternative to clozapine.

Entities:  

Keywords:  antipsychotic agents; clozapine; melperone; schizophrenia

Year:  2011        PMID: 23983923      PMCID: PMC3736899          DOI: 10.1177/2045125311399800

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  9 in total

1.  Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.

Authors:  D M Taylor; L Smith
Journal:  Acta Psychiatr Scand       Date:  2009-02-25       Impact factor: 6.392

2.  Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women.

Authors:  L Bjerkenstedt; B Gullberg; C Härnryd; G Sedvall
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979

3.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

4.  A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

Authors:  H Y Meltzer; B Bastani; K Y Kwon; L F Ramirez; S Burnett; J Sharpe
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Melperone in the treatment of neuroleptic-resistant schizophrenia.

Authors:  H Y Meltzer; T Sumiyoshi; K Jayathilake
Journal:  Psychiatry Res       Date:  2001-12-31       Impact factor: 3.222

7.  Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.

Authors:  R A Lahti; D L Evans; N C Stratman; L M Figur
Journal:  Eur J Pharmacol       Date:  1993-06-04       Impact factor: 4.432

Review 8.  Does the addition of a second antipsychotic drug improve clozapine treatment?

Authors:  Corrado Barbui; Alessandra Signoretti; Serena Mulè; Marianna Boso; Andrea Cipriani
Journal:  Schizophr Bull       Date:  2008-04-23       Impact factor: 9.306

9.  High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing.

Authors:  Carol Paton; Thomas R E Barnes; Mary-Rose Cavanagh; David Taylor; Paul Lelliott
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.